Search Results

Ascendis Pharma A/S announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency has granted marketing authorization for YORVIPATH® in Great Britain as a parathyroid hormone replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, and has also granted YORVIPATH orphan drug status.

Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively investing billions in hopes of treating cancer, Alzheimer’s disease, cardiometabolic disease and more.

Soligenix, Inc. announced that it has received notice of intent to grant additional patents based on its patent application titled “Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines” in the United Kingdom and South Africa, with other international jurisdictions pending.

Life Molecular Imaging and Oryx Isotopes Industrial Company have announced a strategic partnership for the production and distribution of Florbetaben in the Kingdom of Saudi Arabia and other reachable countries, aiming to enhance the supply of this tracer for Amyloid-PET imaging in the Middle East and North Africa region.

AliveDx announced it has now received IVDR Certification for both its state-of-the-art manufacturing facilities located in Eysins, Switzerland and Edinburgh, United Kingdom.

GRI Bio, Inc. today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the UK.

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with Neomorph to discover and develop molecular glue degraders.